2025 Japan Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 Japan Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in Japan include Bayer AG, Regeneron Pharmaceuticals Inc., Roche Holding AG, and Astellas Pharma Inc. Bayer, through its subsidiary Bayer Yakuhin, markets Eylea (aflibercept), an approved treatment for wet AMD and related conditions in Japan. Regeneron collaborates with Bayer on Eylea's global development and holds exclusive marketing rights in the US, while Bayer covers territories outside the US. Roche is a major player internationally with its Lucentis product, also present in Japan's AMD market. Astellas Pharma, a Japanese company, has recently submitted a New Drug Application for avacincaptad pegol, a synthetic aptamer targeting geographic atrophy secondary to AMD, potentially the first approved treatment for this form in Japan.
These companies drive Japan's expanding AMD market, which is projected to grow significantly due to Japan's aging population and increasing prevalence of AMD. Eylea leads the product segment by revenue, followed by Lucentis and the emerging Beovu, reflecting competitive therapeutic options. Research collaborations and regulatory incentives in Japan facilitate faster development and approval of innovative AMD treatments, including gene and cell therapies, as well as advanced diagnostic technologies. Despite challenges like treatment costs and care accessibility in rural regions, ongoing investments by these companies in clinical advancements and public awareness support market growth and improved AMD patient outcomes throughout Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in Japan include Bayer AG, Regeneron Pharmaceuticals Inc., Roche Holding AG, and Astellas Pharma Inc. Bayer, through its subsidiary Bayer Yakuhin, markets Eylea (aflibercept), an approved treatment for wet AMD and related conditions in Japan. Regeneron collaborates with Bayer on Eylea's global development and holds exclusive marketing rights in the US, while Bayer covers territories outside the US. Roche is a major player internationally with its Lucentis product, also present in Japan's AMD market. Astellas Pharma, a Japanese company, has recently submitted a New Drug Application for avacincaptad pegol, a synthetic aptamer targeting geographic atrophy secondary to AMD, potentially the first approved treatment for this form in Japan.
These companies drive Japan's expanding AMD market, which is projected to grow significantly due to Japan's aging population and increasing prevalence of AMD. Eylea leads the product segment by revenue, followed by Lucentis and the emerging Beovu, reflecting competitive therapeutic options. Research collaborations and regulatory incentives in Japan facilitate faster development and approval of innovative AMD treatments, including gene and cell therapies, as well as advanced diagnostic technologies. Despite challenges like treatment costs and care accessibility in rural regions, ongoing investments by these companies in clinical advancements and public awareness support market growth and improved AMD patient outcomes throughout Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
